IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Sindre Lee-degrd, MD, Ph.d., lege ved Seksjon for forebyggende kardiologi, Avdeling for endokrinologi, sykelig overvekt og forebyggende medisin, Oslo universitetssykehus, og seniorforsker ved Universitetet i Oslo
People who continue semaglutide injections maintain their weight loss better than those who stop
has been testing AI-driven styling tools and conversational assistants designed to guide customers through outfit selection and brand discovery
When you visit Direct Meds, you complete an online medical intake form